Roche (SIX:RO, ROG; OTCQX:RHHBY) has announced that the FDA has approved a label extension to allow the use of Evrysdi (risdiplam) in babies younger than two months old with spinal muscular atrophy (SMA). SMA is a genetic disease associated with progressive muscle wasting and weakness that affects roughly 1 in 11,000 babies. The drug first…